Abstract:
A process for the cyclopropanation of a substituted alkene, comprising the reaction of the alkene with a carbenoide, generated from dibromomethane and a tri-(C2-C8)-alkyl aluminium compound, in the presence of a catalytic amount of a metal compound selected from the group consisting of Lewis acids, metallocenes and metal carbonyl complexes. The process advantageously uses transition metal compounds as catalysts and the dibromomethane can be recovered.The process is especially useful for the preparation of ingredients for the flavour and fragrance industry.
Abstract:
A compound of formula (Ia) or (Ib), wherein in each of formulae (Ia) and (Ib) R1 and R2, independently of one another, are H or CH3, and the use thereof as a sandalwood fragrance.
Abstract:
Methods of treating osteoporosis prophylactically or therapeutically are disclosed. The method of treating osteoporosis includes administering to a patient suffering therefrom an effective amount to treat the osteoporosis of novel 1.alpha.-hydroxyvitamin D.sub.4 and novel analogues 1,25-dihydroxyvitamin D.sub.4 and 1,24-dihydroxyvitamin D.sub.4, the aforementioned compounds having lower toxicity as measured by an LD.sub.50 test in rats when compared to a corresponding vitamin D.sub.3 compound. The method of administering the compound is substantially without occurrence of hypercalcemia.
Abstract:
The disclosure is of methods of treating various skin disorders, including skin cancer, with compounds of novel 1.alpha.-hydroxy vitamin D.sub.4 and novel analogues, thereof, including 1,25 dihydroxy vitamin D.sub.4 and 1,24 dihydroxy vitamin D.sub.4. Novel 1.alpha.-hydroxy vitamin D.sub.4 compounds and compounds of novel analogues suitable for use in the treatment of such disorders are also disclosed herein.
Abstract:
A polymerizable compound represented by Formula (I): ##STR1## where X is a hydrogen atom or a methyl group; Y and Z are independently a hydrogen atom or a fluorine atom; l is an integer of 0 to 14; m and n are independently an integer of 0 or 1; R is represented by Formula (II), (III), or (IV); and when m=1, l.gtoreq.1; ##STR2##
Abstract:
Novel 1.alpha.-hydroxy Vitamin D.sub.4 and novel analogues, 1,25 dihydroxy Vitamin D.sub.4 and 1,24 dihydroxy Vitamin D.sub.4 which are useful for the treatment of disorders of calcium metabolism. Preparation of the novel 1.alpha.-hydroxy Vitamin D.sub.4 starts from ergosterol which is converted in six steps to 22,23-dihydroergosterol. 22,23-dihydroergosterol was irradiated to yield Vitamin D.sub.4 which was converted in four steps to 1.alpha.-hydroxy Vitamin D.sub.4 using a cyclovitamin procedure which produced the novel intermediates, Vitamin D.sub.4 tosylate, 3,5 cyclovitamin D.sub.4 and 1.alpha.-hydroxy cyclovitamin D.sub.4. 1,25 dihydroxy Vitamin D.sub.4 and 1,24 dihydroxy Vitamin D.sub.4 are isolated as biological products of the metabolism of novel 1.alpha.-hydroxy Vitamin D.sub.4 using cultured human liver cells.
Abstract:
The present invention provides compounds of the formula: ##STR1## and the pharmaceutically acceptable salts thereof, wherein: R.sup.1 and R.sup.2 are each alkyl;n is an integer of from 1 to 4;x is oxygen or --(CH.sub.2).sub.m --;m is an integer of from 1 to 3;y is oxygen or sulfur; andp is an integer of from 1 to 4.These compounds are inhibitors of COX-I and/or COX-II, and are useful for the treatment of inflammation-associated disorders.The present invention also provides pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, and a method for treating inflammation-associated disorders in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.
Abstract:
Novel benzonitriles, benzaldehydes and benzyl alcohols of the formula I ##STR1## where R.sup.1 is methyl or ethyl, R.sup.2 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, or C.sub.1 -C.sub.5 -alkyl-substituted cycloalkyl, cycloalkenyl, bicycloalkyl or bicycloalkenyl, X is hydrogen, chlorine or fluorine and Z is --CN, CHO or ##STR2## where R.sup.3 is hydrogen, cyano, C.sub.2 -C.sub.4 -alkynyl, C.sub.2 -C.sub.4 -alkenyl or C.sub.1 -C.sub.4 -alkyl, with the proviso that R.sup.2 is not --CH.sub.2 -CH.dbd.CH--B when B is hydrogen, alkyl or alkenyl and at the same time R.sup.1 is methyl and Z is ##STR3## and with the proviso that R.sup.2 is not methyl or ethyl when R.sup.1 is methyl and at the same time Z is ##STR4## and further more with the proviso that R.sup.2 is not methyl when R.sup.1 is methyl or ethyl and at the same time Z is --CN or --CHO.
Abstract:
The invention provides cyclopentane derivatives of the general formula ##STR1## in which n represents an integer from 0 to 5, each R represents a halogen atom, nitro, cyano, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, alkoxycarbonyl, carboxyl, alkanoyl, alkythio, alkysulphinyl, alkylsulphonyl, carbamoyl, alkylamindo, cycloalkyl or phenyl group, R.sup.1 and R.sup.2 independently represent a hydrogen atom or an alkyl group, and R.sup.3 represents an optionally substituted alkyl or aryl group; and a process for their preparation. Compounds of formulae I, II and IV are useful as intermediates in the preparation of certain fungicidally active cyclopentane derivatives. Also, certain compounds of formula IV are themselves fungicidally active.
Abstract:
Cyclohexane derivatives of the formula IR.sup.1 --A.sup.1 --Z.sup.1 --A.sup.2 --R.sup.2 IwhereinR.sup.1 and R.sup.2 are each H or an alkyl group which has 1-10 C atoms and in which one or two non-adjacent CH.sub.2 groups can also be replaced by 0 atoms and/or --CO-groups, and/or --CO--O-- groups and/or --CH.dbd.CH-- groups, or are F, Cl, Br, CN or R.sup.3 --A.sup.3 --Z.sup.2 --,A.sup.1 is --A--, A.sup.4 --Z.sup.o --A-- or --A--Z.sup.o --A.sup.4 --,A is a trans-1,4-cyclohexylene or 1,4-cyclohexenylene group which is unsubstituted or is monosubstituted or polysubstituted in the 2-, 3-, 5- and/or 6-position by F and/or Cl and/or Br and/or CN and/or an alkyl group or a fluorinated alkyl group each of which has 1-10 C atoms and in which one or two non-adjacent CH.sub.2 groups can also be replaced by 0 atoms and/or --CO-- groups and/or --CO--O-- groups, which trans-1,4-cyclohexylene or 1,4-cyclohexenylene group can optionally also be substituted in the 1-position and/or 4-position and one or two CH.sub.2 groups therein are replaced by --CO--, orR.sup.1 --A.sup.1 -- is a cyclohexyl group which is substituted in the 3-position by an alkyl group which has 1-10 C atoms and in which one or two non-adjacent CH.sub.2 groups can also be replaced by 0 atoms and/or --CO-- groups and/or --CO--O-- groups and/or --CH.dbd.CH-- groups, or is substituted in the 3-position by CN, in which cyclohexyl group one or two nonadjacent CH.sub.2 groups can also be replaced by --O-- or --CO--, A.sup.2, A.sup.3 and A.sup.4 are each 1,4-phenylene which is unsubstituted or substituted by one or two F and/or Cl atoms and/or CH.sub.3 groups and/or CN groups and in which one or two CH groups can also be replaced by N atoms and/or NO, or are 1,4-cyclohexylene wherein one or two non-adjacent CH.sub.2 groups can also be replaced by 0 atoms, or are 1,3-dithiane-2,5-diyl, piperidine-1,4-diyl, 1,4-bicyclo(2,2,2)-octylene, decahydronaphthalene-2,6-diyl or 1,2,3,4-tetrahydronaphthalene-2,6-diyl groups or are --A--, Z.sup.o, Z.sup.1 and Z.sup.2 are each --CO--O--, --O--CO--, -- CH.sub.2 CH.sub.2 --, --OCH.sub.2 --, --CH.sub.2 O--, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 CHCN--, --CHCNCH.sub.2 -- or a single bond, andR.sup.3 is H or an alkyl group which has 1-10 C atoms and in which one or two non-adjacent CH.sub.2 groups can also be replaced by 0 atoms and/or --CO-- groups and/or --CO--O-- groups and/or --CH.dbd.CH-- groups, or is F, Cl, Br or CN, are suitable for use as components of liquid-crystal phases.